Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19
Veristat helps Antibe Therapeutics complete their Phase IIB study during COVID-19 and will deliver top-line results to Antibe in six weeks.
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
1 min read
Veristat News : Published Updated
Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346.
Veristat will conduct the study in a total of 360 patients with osteoarthritis (“OA”) of the knee, across approximately 35 clinical sites in Canada. Using our proven patient recruitment and site engagement techniques, we will commence enrollment immediately.
Read the full press release on the Antibe Therapeutics website.
Veristat’s full-
service clinical development solutions are ideal for emerging and small to mid-size biopharmaceutical companies. We deliver uncompromised value and impact to our clients as we guide them from early phase trial planning and design, through to trial execution, regulatory submission support through to post-approval.
Veristat helps Antibe Therapeutics complete their Phase IIB study during COVID-19 and will deliver top-line results to Antibe in six weeks.
Veristat Strengthens Its European Presence with the Acquisition of TCTC Group, therefore, increasing Its Geographic Footprint and Expanding...
Veristat and Cidara Therapeutics Collaborate with a Preferred Provider Agreement